Physicians' Education Resource®, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by an educational grant from Pfizer Inc.
Date: Thursday February 8, 2018
Time: 7:00 PM – 9:00 PM
Dinner and registration: 6:30 PM – 7:00 PM
Location: Marriott Marquis,
780 Mission St.
San Francisco, CA 94103
Room: Golden Gate A
Renal cell carcinoma (RCC) remains one of most difficult to treat of the solid tumors. However, RCC treatment is also one of the most rapidly evolving fields in oncology. New data suggest impending changes in both early-stage and metastatic RCC, including novel indications, combination approaches, and optimized adjuvant strategies. However, the use of adjuvant therapy for RCC remains an area of controversy. This activity will bring together renowned experts in RCC for in-depth critical review and debate on evidence from studies of adjuvant RCC therapy. To help clinicians synthesize available information, this satellite symposium will include didactic overviews of current data on adjuvant therapy, risk assessment, and patient selection; case reviews; and faculty debates on key areas of controversy and clinical uncertainty around the use of adjuvant therapy for RCC. The format of this activity will enable the audience to interact with the expert faculty panel and to gain evidence-based perspective on the use of adjuvant therapy for RCC.
This activity is supported by educational an grant from Pfizer Inc.
This educational program is directed toward urologists, medical oncologists, surgical oncologists, and radiation oncologists interested in the treatment of RCC. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with RCC will be invited to participate.
Upon completion of this activity, participants should be better prepared to:
Robert A. Figlin, MD, FACP
Steven Spielberg Family Chair in Hematology Oncology
Professor of Medicine and Biomedical Sciences
Director, Division of Hematology/Oncology
Deputy Director, Integrated Oncology Service Line
Deputy Director, Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, CA
ONS: PER Forum™: Nursing Opportunities to Improve Outcomes With the Advent of PARP Inhibitors in the Care of Women’s Cancers
May 17, 2018
ONS: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for Nurses
May 17, 2018
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of Cancers
May 30, 2018
May 31, 2018
May 31, 2018